Health
Fosun Pharma Announces 2025 Interim Results
Enhancing Innovation Efficiency and Steadily Expanding Globally SHANGHAI, Aug. 26, 2025 /PRNewswire/ -- On August 26, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma" or "the Group"; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced ...
2025-08-26 20:42
1950
Brightonix Imaging's High-Performance 'PHAROS' PET Receives FDA Clearance
SEOUL, South Korea, Aug. 26, 2025 /PRNewswire/ -- Brightonix Imaging, a global leader in cutting-edge medical imaging technology, is proud to announce that its flagship product, thePHAROS PET Scanner, has received FDA clearance for commercial distribution inthe United States. This milestone marks...
2025-08-26 19:00
1281
Peijia Medical Announces 2025 Interim Results
HONG KONG, Aug. 25, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six months endedJune 30, 2025 ("the Reporting Period") on August 22...
2025-08-25 20:00
2169
Akeso Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4Rα) for Atopic Dermatitis Achieve Primary Endpoints
HONG KONG, Aug. 25, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) ("Akeso" or "the Company") today announced positive results from its Phase 3 clinical trial of gumokimab (AK111), a novel, fully human anti-IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis (AS). The study ...
2025-08-25 13:46
1270
Harbour BioMed Appoints Yajie Li as Chief Medical Officer
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 24, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointment...
2025-08-25 09:00
1848
Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer
SAN FRANCISCO and SUZHOU, China, Aug. 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company committed to developing, manufacturing and commercializing high-quality medicines in oncology, cardiovascular and metabolic diseases, autoimm...
2025-08-25 08:00
1685
WINVEST GROUP SUBSIDIARY IQI MEDIA PARTNERS WITH BIOCALTH TO DRIVE DIRECT-TO-CONSUMER SALES
RENO, Nev., Aug. 22, 2025 /PRNewswire/ -- Winvest Group Limited (OTCQB: WNLV) ("Winvest"), an investment holding company with diverse media, entertainment, and technology portfolios, is pleased to announced that its subsidiary IQI Media Inc. has partnered with BioCalth International Inc., a world...
2025-08-22 20:00
3189
Heartbeats Launches Digital Wellness Platform Led by World-Renowned Heart Specialist Dr. Hosen Kiat
SYDNEY, Aug. 22, 2025 /PRNewswire/ -- In an online world awash with wellness
fads and misinformation, one of the world's most cited cardiologists has
decided to step in.Dr Hosen Kiat
2025-08-22 13:22
1993
Orange Biomed Lands on Fortune Korea's Top 40 with Portable Diabetes Test
SEATTLE, Aug. 21, 2025 /PRNewswire/ -- Orange Biomed, developer of the world's first pocket-sized A1C testing device, is receiving international recognition for its breakthrough microfluidic technology designed to enhance accessibility and accuracy in chronic disease management. The company has b...
2025-08-22 00:00
1595
SK bioscience Discusses Further Collaboration with the Gates Foundation to Advance Global Health
* Company holds a dedicated meeting with Gates Foundation executives during Bill Gates' visit to Korea. * Both reviews expanded cooperation, including next-generation preventive medicines. SEONGNAM, South Korea, Aug. 21, 2025 /PRNewswire/ -- SK bioscience, a global innovative vaccine and biot...
2025-08-21 20:00
1676
BioDlink's Bevacizumab Approved for Market Launch in Indonesia, Marking Fourth Consecutive Emerging Market Authorization
* Bevacizumab Injection officially approved by Indonesia's National Agency of Drug and Food Control (BPOM), following Nigeria, Pakistan, and Colombia – accelerating global commercialization * Approval in ASEAN's largest pharma market strengthens BioDlink's position as a global supplier of ant...
2025-08-21 20:00
1477
FDA clearance of Salix® Coronary Plaque module
Significantly expands U.S. commercial opportunity with ability to charge fees per scan assessed Investor Webinar - 11.30am AEST (9.30am AWST) on 22 August 2025 PERTH, Australia, Aug. 21, 2025 /PRNewswire/ -- Artrya Limited (ASX: AYA) ( Artrya or the Company), a medical technology company commerc...
2025-08-21 19:43
1637
Waterdrop Inc. to Report Second Quarter 2025 Financial Results on September 4, 2025
BEIJING, Aug. 21, 2025 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH) ("Waterdrop" or the "Company"), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced that it will report its unaudited financial results for the second quarter e...
2025-08-21 18:00
2403
GC Biopharma's Study on Hunterase Lysosomal Delivery Mechanism Published in SCIE-Indexed Journal
YONGIN, South Korea, Aug. 21, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based inSouth Korea, announced today that it has revealed the delivery mechanism of Hunterase (idursulfase beta), a recombinant enzyme replacement therapy for Hunter syndrome (MPS II). The res...
2025-08-21 13:00
1352
Zylox-Tonbridge Announces 2025 Interim Results: Strong Revenue Growth with Net Profit Surging Over 76% Year-over-Year
HANGZHOU, China, Aug. 20, 2025 /PRNewswire/ -- Zylox-Tonbridge Medical Technology Co., Ltd. (HKEX: 2190, hereinafter referred to as "Zylox-Tonbridge" or the "Company") today announced its interim results for the six months ended June 30, 2025. The Company achieved robust revenue growth of 31.7% y...
2025-08-20 21:41
2623
Cell therapy is promising in treating psychiatric disorders, such as depression. -- A proof-of-principle study published in "Cell Stem Cell" by the laboratory of Dr. Chen, founder of UniXell Biotech, suggests this.
SHANGHAI, Aug. 20, 2025 /PRNewswire/ -- On August 11, 2025, the research team led by Professor Yuejun Chen, founder of UniXell Biotech, published an article titled "Human stem cell-derived A10 dopaminergic neurons specifically integrate into mouse circuits and improve depression-like behaviors" i...
2025-08-20 20:49
2192
Ping An Good Doctor (1833.HK) Reports Solid Interim Results with Steady Revenue and Profit Growth
HONG KONG, Aug. 20, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited (the "Company"; Stock Code: 1833.HK) announced its interim results for the six months endedJune 30, 2025, on August 19, 2025. Following its return to profitability in 2024, the Company maintained high growt...
2025-08-20 19:19
2370
Dubai Humanitarian: Powerful New Documentary Reveals World's Largest Humanitarian Logistics Hub
- 'Coming Together: The Dubai Humanitarian Story' provides behind-the-scenes look inside the heart of global disaster response facility - Launches on World Humanitarian Day, 19 August 2025 - First six months of 2025 saw $48.8m humanitarian aid distributed from Dubai Humanitarian, reflected in it...
2025-08-20 17:47
1726
First Patient Dosed in Pivotal Phase III Trial of Cadonilimab (PD-1/CTLA-4) for Perioperative Treatment of Resectable Gastric Cancer
HONG KONG, Aug. 20, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced the enrollment and dosing of the first patient in the pivotal Phase III clinical trial (AK104-310/COMPASSION-33) evaluating cadonilimab, a first-in-class PD-1/CTLA-4 bispecific antibody developed b...
2025-08-20 16:11
1437
Ping An Good Doctor (1833.HK) Reports Strong Interim Results: Revenue and Profit Accelerate as AI Fuels New Growth Momentum
HONG KONG, Aug. 19, 2025 /PRNewswire/ -- Ping An Healthcare and Technology Company Limited("Ping An Good Doctor" or the "Company"; Stock Code: 1833.HK) announced its interim results for the six months endedJune 30, 2025. During the first half of 2025, the Company delivered steady operational perf...
2025-08-19 23:11
3269
Week's Top Stories
Most Reposted
Senetas and Nokia Announce Strategic Alliance to Secure Mission-Critical Networks for Defence and Government
[Picked up by 312 media titles]
2025-11-27 07:25World-Leading Microsurgeon Professor J.P. Hong Joins MediThinQ as CMO, Marking Strong Validation for Next-Generation Digital Microsurgery
[Picked up by 296 media titles]
2025-12-03 09:00
SpeQtre, the entanglement-based quantum comms demonstrator satellite, is now on orbit
[Picked up by 295 media titles]
2025-11-29 09:00
Blackpanda and ST Engineering Partner to Strengthen Cyber Incident Response Across Asia
[Picked up by 285 media titles]
2025-12-03 14:27
MetaOptics Announces Strategic Share Placement to Accelerate Growth and Meet Rising Global Demand
[Picked up by 284 media titles]
2025-12-01 08:30Most Read
MINISO Unveils Australia's First and Largest MINISO LAND Flagship at Sydney Chatswood
2025-11-27 18:56
2734
